IRONWOOD PHARMACEUTICALS, INC. Unamortized Debt Issuance Expense
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Unamortized Debt Issuance Expense of $494.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2025-11-10
- 2025-09-30: Unamortized Debt Issuance Expense $494.00K.
- 2025-06-30: Unamortized Debt Issuance Expense $668.00K.
- 2025-03-31: Unamortized Debt Issuance Expense $840.00K.
- 2024-12-31: Unamortized Debt Issuance Expense $1.01M.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2025-09-30 | $494.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $668.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $840.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.01M 10-Q · filed 2025-11-10 |
| 2024-09-30 | $1.18M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.35M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.72M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.13M 10-Q · filed 2024-11-07 |
| 2023-09-30 | $2.54M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.94M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $3.35M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $3.75M 10-Q · filed 2023-11-09 |
| 2022-09-30 | $4.15M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.55M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $5.07M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $4.87M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $5.31M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.73M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.14M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $6.54M 10-Q · filed 2021-11-04 |
| 2020-09-30 | $6.93M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.30M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $7.66M 10-Q · filed 2020-05-06 |
| 2019-09-30 | $8.34M 10-Q · filed 2019-10-31 |
| 2015-12-31 | $7.44M 10-K · filed 2017-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |